(Reuters) – U.S. Food and Drug Administration on Tuesday changed its estimate for the availability of lower doses of Novo Nordisk’s weight-loss drug Wegovy to “to be decided” from its earlier expectation of September.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
